Kornimate/medical-research-clean huggingface dataset:
ssris and tdcs enhance post-stroke motor recovery

Conditions: Stroke; Motor

Summary: post-stroke motor recovery is compelling but limited. current rehabilitation has less impacts on the plateau that spontaneous biological recovery could be expected. the advances in non-invasive neuromodulation and neurophysiological characterization of critical motor recovery period enable breaking the proportional recovery limitation. our pilot studies demonstrated the safety and responsiveness of combing dual transcranial direct current stimulation (tdcs) and motor training in subacute stroke patients. there is also strong evidence that selective serotonin reuptake inhibitors (ssris) can substantially increase the effects of tdcs and improve motor function after stroke, even in the absence of depression. this proposal aims to prove the potential of combining of tdcs and the commonly used ssri citalopram to improve response to a daily motor training intervention in acute stroke patients (co-stars trial).

this is a randomized, double-blind, sham-controlled study in 80 patients with first-ever, unilateral, subcortical ischemic stroke 0.5-4 weeks after stroke onset with moderate to severe hemiparesis. participants were randomized into four groups underwent either real dual tdcs \[ipsilesional primary motor cortex (m1) anodal stimulation and contralesional m1 cathodal stimulation; 2 ma for 20 mins; 10 sessions within 2 weeks\] with citalopram or placebo, or sham stimulation with citalopram or placebo. all will receive concurrent hospitalized intensive rehabilitation of 2 daily sessions of 90-minute physiotherapy. action reach am test (arat), fugl-meyer assessment (fma), multimodality mri and eeg will be measured at baseline and after 2 weeks' tdcs modulation. the primary outcome is the arat at 3 months after intervention. the combination of tdcs and a ssri will be expected to improve response to motor training more effectively than either intervention alone. the enhanced responsiveness will be correlated or predicted by biomarkers from multimodality mri or eeg.

Eligibility criteria:
inclusion criteria: * aged 20-80; * first-onset stroke * brain image confirmed unilateral subcortical infarction * moderate to severe upper-limb impairment (safe score \<8). * 3 days to 4 weeks after stroke onset * stable medical condition exclusion criteria: * metal implants, such as electrodes or pacemaker * epilepsy history or active spikes from eeg recording * major depression or taking psychoactive drugs * alcoholism or drug abuse history * combined with other severe neurological or psychiatric diagnoses * pregnancy or breastfeeding; * other contraindications to brain mri, such as severe claustrophobia * intolerance to electrical stimulation

Keywords: stroke, motor recovery, transcranial direct current stimulation, selective serotonin reuptake inhibitors
registry-based study in patients with hepatitis d virus (hdv) infection in china

Conditions: Hepatitis D

Summary: this is a retrospective, prospective, noninterventive, multicenter registry study. patients diagnosed with hdv infection (based on positive hdv rna) were included in this study and were followed up for at least 5 years to evaluate their disease progression and clinical outcomes (including death, liver transplantation, hepatocellular carcinoma \[hcc\], liver decompensation, and cirrhosis) during the 5-year follow-up period. all patients were followed up at least once a year after they were included in the study. it was in 2016 hdv infection first reported in china. since january 1, 2016, all patients diagnosed with hdv infection can be enrolled in this study and evidence confirming the diagnosis (including but not limited to hdv rna test reports and medical records, etc.) must be delivered. the main test results (including serum hdv rna, alt, and tests to determine the presence of liver cirrhosis, decompensation of liver function, and liver cancer such as b-ultrasound and fibroscan) of these patients each year from diagnosis to enrollment should be collected and filled in the case report form (crf). follow-up data of patients with serum anti-hdv positive and hdv rna negative can be recorded and followed up on this platform, with informed consent of the patients is required. patients whose serum hbv rna turn positive during the follow-up period will be included in the follow-up cohort of the study.


Eligibility criteria:
inclusion criteria: * adults aged 18 or above, both sex; * evidence of a positive test for hdv rna can be provided on or before the enrollment date; * able to sign written informed consent.

Keywords: hepatitis d virus
longitudinal cohort of pediatric primary immune thrombocytopenia (itp)

Conditions: Primary Immune Thrombocytopenia

Summary: immune thrombocytopenic purpura (itp) is a kind of rare childhood disease that involve autoimmune destruction of platelets.the current pediatric itp cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in china. there is a lack of comprehensive and large-scale prospective cohort studies in pediatric itp. the purpose of this study is to analyze the clinical characteristics of pediatric itp, the treatment methods, prognosis and prognostic model of these patients in china.

immune thrombocytopenia (itp) is an organ-specific autoimmune disease, which is characterized by decreased platelet count and skin and mucosal bleeding. itp is a kind of disease with increased platelet destruction and impaired platelet production caused by autoimmunity. conventional treatment of adult itp includes first-line glucocorticoid and immunoglobulin therapy, second line tpo and tpo receptor agonist, splenectomy and other immunosuppressive treatments (such as rituximab, vincristine, azathioprine, etc.). itp is one of the most common hemorrhagic diseases. at present, the treatment response of itp is not good, and a considerable number of patients need drug maintenance treatment, which seriously affects the quality of life of patients and increases the economic burden of patients. longitudinal cohort allows to describe the long-term clinical characteristics of pediatric itp patients, to study the benefit-risk balance of treatments, including the growing development of targeted therapies and to analyze the prognostic factors and attempts to establish prognostic models. the study will include pediatric patients diagnosed with primary immune thrombocytopenia in the investigating hospitals, and collect basic information, diagnostic and treatment information from medical records. the study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.

Eligibility criteria:
inclusion criteria: * age 6-17 years old (including both ends), male and female; * diagnosis of itp. exclusion criteria: * secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.; * the expected follow-up period is less than 3 months.
spanish series of patients treated with the radionuclide lutetium177

Conditions: Neuroendocrine Tumors; Intestinal Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Endocrine Gland Neoplasms; Digestive System Diseases; Gastrointestinal Disease; Intestinal Diseases; Pancreatic Disease; Endocrine System Diseases

Summary: this study aims to pool the clinical experience of spanish centers treating patients with 177lu-dotatate to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.

patient data will be collected from medical records after obtaining consent and retrospectively.

Eligibility criteria:
inclusion criteria: * written informed consent must be obtained prior to any data collection. * patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour * aged ≥18 years. exclusion criteria: * none

Keywords: gep-net gastro-entero-pancreatic neuroendocrine tumour luthatera somatostatin receptor positive tumour
cervical length pre-induction as a tool to predict vaginal birth

Conditions: Cervical Length Measurement; Pregnancy, Prolonged

Summary: to evaluate the value of measuring cervical length as a predictor of vaginal birth after induction of labor with prostaglandins in pregnancies with 41 weeks of gestation.


Eligibility criteria:
inclusion criteria: * 41 weeks or more of gestational age * cervical length measured by a fmf certified physician exclusion criteria: * any condition that could interfere with a possible vaginal birth (previous cesarean section, hypertensive disorders of pregnancies).

Keywords: cervical length prolonged pregnancy vaginal birth
virtual visits for results disclosure

Conditions: Genetic Disease

Summary: as part of this study patients who have undergone genetic testing in the brigham and women's hospital cardiovascular genetics program will be randomized to receive the results of their genetic testing either by telephone call or virtual visit. at the completion of the telephone call or virtual visit patients will receive a survey to assess their understanding of their results and their satisfaction with their care.


Eligibility criteria:
inclusion criteria: * 18 years or older * undergoing genetic testing at bwh cardiovascular genetics clinic exclusion criteria: * reside outside of massachusetts * telephone or internet access unavailable
efficacy of inpatient pulmonary rehabilitation program in elderly patients with acute exacerbation of copd

Conditions: COPD Received PR; Elderly (People Aged 65 or More); COPD; COPD Acute Exacerbation

Summary: the study aimed to identify the effect of early pulmonary rehabilitation in elderly patients with acute exacerbation (ae) of copd (aecopd) in exercise tolerance, dyspnea, sleep quality, fatigue, and time to discharge from hospital.

a prospective supervised rct (randomized controlled trial) will be done include elderly copd patients assigned randomly into two groups; group a performed physical therapy program, and group b is control group completed two daily sessions from day 1 of hospital admission till discharge from the hospital .the study duration will be 12 weeks

Eligibility criteria:
inclusion criteria: * patients with acute exacerbation of copd in both gender * patient older than 65 years * patient with clear consciousness * patients had been diagnosed with shortness of breath or dyspnea that was not caused by heart disease, pneumothorax, or pulmonary edema exclusion criteria: * patient with systolic blood pressure lower than 90 mmhg * patient with an unstable psychological status, hemoptysis, pneumothorax, pulmonary edema

Keywords: elderly patients with acute exacerbation of copd
comparative evaluation of an electrical impedance device versus digital radiography in estimation of remaining dentin thickness

Conditions: Caries,Dental; Deep Caries

Summary: the research question was that in patients with carious posterior permanent teeth, would the electrical impedance device be as valid as digital radiography in estimation of remaining dentin thickness? the proposed hypothesis was null.


Eligibility criteria:
inclusion criteria: * participants eligible for this study were those aged from 18 y to 28 y, * willing to join the study * with clinically detectable occlusal or proximal carious vital permanent molar teeth with closed apex and healthy periodontal supporting. * the minimum extension of the carious cavity should be at least 1 mm in width to accommodate with the probe of the prepometer exclusion criteria: * excluded participants were those with poor oral hygiene, * severe medical complications, * showing signs and symptoms of irreversible or necrotic pulp pathology also when the affected tooth was with extended buccal or lingual caries, extending clinically beyond ¼ dentin thickness or previously restored.

Keywords: electrical impedance device (prepometer) digital radiography remaining dentin thickness
evaluation of the effectiveness of a muscular strengthening protocol with an instrumented orthosis for gonarthrosis patients

Conditions: Gonarthrosis

Summary: the management of knee osteoarthritis via a physical activity protocol for rehabilitation has convincing results. however, the effectiveness of these protocols could be improved with a connected instrumented knee brace with an exercise protocol adapted for the patient which is supervise by an online physiotherapist to check the progression during home-based rehabilitation.

the management of knee osteoarthritis via physical activity protocol for rehabilitation has convincing results. the aim of this study is to determine the improvement of the effectiveness of a home-based rehabilitation with and without instrumented knee brace for moderated gonarthrosis patients. the study will focus during one years on 80 moderated gonarthrosis patients with a kellgren and lawrence (k\&l) score between 2 and 3, aged between 50 and 80. each patient will practice an 8 weeks progressive home exercise program with 3 session per weeks. the effectiveness of this protocol will be quantified with a gait analysis with kinematics, kinetics and electromyography, before and after the progressive home exercise protocol. the statistical analysis will focus on anova and correlation between control group and instrumented knee brace group.

Eligibility criteria:
inclusion criteria: * person who signed informative consent * affiliated with the social security * male and female aged between 50 and 80 * walk without assistance * smartphone's use exclusion criteria: * person under protective measure * orthopedics issues * neurologic issues (mmse test \< 24) * knee or hip prothesis * person with nsaids and analgesics treatment with an effective intake less than 48 hours before the evaluation * predominant patello-femoral arthritis * symptomatic hip oa * knee infection * knee injuries
emergency care action plans for infants with medical complexity

Conditions: Children with Medical Complexity; Child, Only; Infant Morbidity; Infant Conditions; Utilization, Health Care; Emergencies; Chronic Condition

Summary: an emergency care action plan (ecap) is a tool intended to be helpful to providers when treating a child with complex medical needs during an emergency. once created, ecaps are added to the electronic health record (ehr), shared with the child's caregiver(s), and kept up by all of those involved in a child's care. the goal of this study is to measure important health outcomes (ex. inpatient days, emergency department visits) in terms of the use of the ecap for infants discharged from the neonatal intensive care unit (nicu). this study will also measure other real-time potential challenges related to the use of the ecap including, but not limited to, if it is being used, if providers and caregivers want to use it, and if they keep using it over a long period of time.

national expert recommendations and human-centered design principles were used to optimize an emergency care action plan (ecap) for infants with medical complexity. this study will implement and monitor the effectiveness and feasibility of the optimized emergency care action plan for infants with medical complexity. the primary objective is to determine the effectiveness of a user-centered emergency care action plan for infants with medical complexity on emergency health care utilization and cost metrics. the secondary objective is to monitor and evaluate barriers and facilitators to the current and widespread implementation of a user-centered emergency care action plan for infants with medical complexity. research participants will be assigned by chance to receive an ecap or standard care. caregivers (parent/legal guardian) of infant participants will be asked to complete periodic surveys during a one-year feasibility trial period. if assigned, caregivers will be asked to help with the process of creating an ecap for their child.

Eligibility criteria:
inclusion criteria: * age 0 to 6 months * admitted to the university of vermont medical center neonatal intensive care unit (nicu) * meets or is expected to meet children with medical complexity status as determined by the treating nicu clinician and defined as "children with multiple significant chronic health problems including multiple organ systems, which result in functional limitations, high health care needs or utilization, and often require need for, or use of, medical technology." exclusion criteria: * does not have a caregiver participant who agrees to their participation in the study to complete follow-up surveys * does not intend to use university of vermont health network and affiliated sites for care during the one-year trial period
salvage therapy with chemotherapy and natural killer cells in relapsed/refractory paediatric t cell lymphoblastic leukaemia and lymphoma

Conditions: Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma

Summary: to determine safety profile of immunotherapy with natural killer cells and activated expanded (nkaes) after salvage chemotherapy in relapsed/refractory paediatric t cell lymphoblastic leukaemia and lymphoma.


Eligibility criteria:
inclusion criteria: * patients aged between 0 and 21 years with relapsed or refractary acute lymphoblastic leukemia or t-cell lymphoblastic lymphoma. * lansky index \> 60%. * left ventricular ejection fraction \> 39%. * negative hiv serology. * provide informed consent in accordance with current legislation. exclusion criteria: * patients with a history of poor compliance. * patients not valid after psycho-social evaluation * severe (4) functional organ disorders (hepatic, renal, respiratory) according to nci ctcae v3 criteria

Keywords: immunotherapy nkaes expanded haploidentical natural killer cells activated natural killer cells
luveltamab tazevibulin (stro-002) in infants and children < 12 years of age with relapsed/refractory cbfa2t3::glis2 aml

Conditions: Acute Myeloid Leukemia (AML)

Summary: this trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of aml carrying a particular genetic abnormality called cbfa2t3::glis2 that arises in infants and children. to be treated in this trial children must have a leukemia which did not respond or recurred after prior treatment. luveltamab tazevibulin is an antibody-drug conjugate, which brings tazevibulin, an anticancer drug, to a molecule called folr1, present on the surface of cbfa2t3::glis2 aml cells.

this is a registrational international, multicenter, two-part open label phase 1/2 trial in an extremely rare pediatric disease (around 17 new patients a year in us and 10 in eu). part 1 randomizes subjects 1:1 to one of two luveltamab tazevibulin dose cohorts (1a and 1b). part 2 further evaluates the safety and the efficacy of the selected dose. subjects who achieve complete remission after two cycles of treatment may continue luveltamab tazevibulin as monotherapy, while non-responders at pi discretion may add luveltamab tazevibulin with stadard of care (soc) aml treatments. luveltamab tazevibulin is given iv every two week as monotherapy and every 4 weeks when given with chemotherapy.

Eligibility criteria:
inclusion criteria: * aml with cbfa2t3::glis2 gene fusion centrally confirmed * refractory or relapsed disease with ≥ 5% bone marrow involvement with leukemic blasts by morphology * age \< 12 years. * lansky performance of ≥ 50 * adequate organ functions exclusion criteria: * active central nervous system (cns) disease (cns3) * pre-existing clinically significant corneal disorders or constitutional diseases associated with an increased risk of aml treatment toxicities * active or uncontrolled infections or other active severe intercurrent illnesses, * prior treatment with a folr1- targeting adcs or with adcs that contain a tubulin inhibitor * history of allogeneic hematopoietic stem cell transplant or any organ transplant in the prior 84 days * graft versus host disease (gvhd) of any grade or gvhd treatment with exception of low dose steroids

Keywords: cbfa2t3::glis2 fusion cbfa2t3::glis2 aml ram phenotype (cd56pos); cd45, cd38, hla-dr weak or absent) reframe aml, child pediatric aml levelatamab reframe-p1
development and validation of a short tool to assess the awareness of pregnancy-induced hypertension

Conditions: Pregnancy Related; Hypertension in Pregnancy

Summary: background: pregnancy-induced hypertension (pih) is responsible for most perinatal and fetal mortality. few programs are patient-centered during pregnancy, increasing the risks of misinformation and misconceptions among pregnant women and, as a result, malpractices. objective: this study aims to develop and validate a form to assess the knowledge and attitudes of pregnant women about pih.

many observational studies explored the awareness of pregnant women of pih, but no structured tool is available to assess such awareness. during the past two years, education campaigns were postponed and primary care was prioritized. to allow better-informed decisions and targeted actions, this pilot study aims to develop and validate a short form to assess the knowledge and attitudes of pregnant women about pregnancy-induced hypertension. the long-term objective of this study is to provide a practical tool for pregnant women.

Eligibility criteria:
inclusion criteria: * participants were asked to participate in the study with no criteria based on race, ethnicity, or gestational age. exclusion criteria: * those with a history of hypertension or pre-eclampsia were excluded.